Yes, Tivicay (dolutegravir) and Truvada (emtricitabine/tenofovir disoproxil fumarate) can absolutely be taken together and represent a highly effective HIV treatment combination.
Guideline-Based Recommendation
This combination of dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF/FTC) is explicitly recommended as a first-line antiretroviral therapy regimen for most people with HIV 1. The 2025 International Antiviral Society-USA guidelines list "Dolutegravir plus TXF/XTC" (where TXF/XTC includes TDF/FTC, which is Truvada) as one of the preferred initial regimens with an AIa evidence rating—the highest level of recommendation 1.
FDA Label Confirmation
The FDA-approved prescribing information for Tivicay confirms that dolutegravir is indicated "in combination with other antiretroviral agents" for HIV-1 treatment 2. Importantly, the drug label specifically states that tenofovir can be coadministered with dolutegravir without dose adjustment—there are no clinically significant drug interactions between these medications 2.
Clinical Evidence Supporting This Combination
Multiple high-quality studies demonstrate the efficacy and safety of this exact combination:
The GEMINI trials compared dolutegravir + lamivudine versus dolutegravir + TDF/FTC in treatment-naive adults, showing that 93% of participants on dolutegravir + TDF/FTC achieved viral suppression (HIV-1 RNA <50 copies/mL) at 48 weeks 3. This demonstrates robust efficacy of the dolutegravir + Truvada combination.
The ADVANCE study evaluated dolutegravir + TDF/FTC versus efavirenz-based therapy, with 78% of participants on dolutegravir + TDF/FTC maintaining viral suppression at 96 weeks 4.
The VESTED trial in pregnant women showed that dolutegravir + TDF/FTC achieved 91% viral suppression at delivery, demonstrating safety and efficacy even in this vulnerable population 5.
Practical Considerations
Dosing is straightforward: Take dolutegravir 50 mg once daily plus Truvada (TDF 300 mg/FTC 200 mg) once daily. Both can be taken at the same time, with or without food.
Key monitoring points:
- Renal function should be monitored due to tenofovir disoproxil fumarate, particularly in patients with baseline kidney disease or those taking other nephrotoxic medications
- Bone density monitoring may be warranted with long-term TDF use
- No dose adjustment is needed for the combination itself
Common pitfall to avoid: If the patient is taking medications containing polyvalent cations (calcium, iron, magnesium, aluminum antacids), dolutegravir should be taken 2 hours before or 6 hours after these agents, OR taken together with food 2.
This combination represents a proven, guideline-recommended regimen with extensive clinical trial data supporting its use for HIV treatment.